Radius Health, Inc. (NASDAQ:RDUS) VP Brent Hatzis-Schoch acquired 1,778 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The stock was bought at an average cost of $28.09 per share, with a total value of $49,944.02. Following the completion of the transaction, the vice president now directly owns 2,278 shares in the company, valued at $63,989.02. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of Radius Health, Inc. (NASDAQ:RDUS) traded down $1.36 during midday trading on Wednesday, hitting $26.35. 2,205,500 shares of the stock were exchanged, compared to its average volume of 970,488. Radius Health, Inc. has a twelve month low of $24.66 and a twelve month high of $55.97. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87.
Radius Health (NASDAQ:RDUS) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The firm had revenue of $13.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same quarter last year, the firm earned ($1.07) earnings per share. analysts forecast that Radius Health, Inc. will post -5.4 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://ledgergazette.com/2017/11/15/brent-hatzis-schoch-purchases-1778-shares-of-radius-health-inc-rdus-stock-2.html.
RDUS has been the topic of several research reports. Zacks Investment Research upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Cantor Fitzgerald reiterated a “buy” rating and issued a $58.00 price target on shares of Radius Health in a report on Friday, November 3rd. Jefferies Group LLC reiterated a “hold” rating and issued a $38.00 price target (up previously from $34.00) on shares of Radius Health in a report on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $45.00 price target on shares of Radius Health in a report on Friday, October 6th. Finally, Canaccord Genuity set a $85.00 price target on shares of Radius Health and gave the stock a “buy” rating in a report on Monday, July 31st. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $51.00.
Hedge funds and other institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC purchased a new position in shares of Radius Health during the 3rd quarter valued at approximately $110,000. Sei Investments Co. lifted its holdings in Radius Health by 27.7% in the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 690 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Radius Health by 19.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 541 shares in the last quarter. Advisor Group Inc. lifted its holdings in Radius Health by 267.2% in the 2nd quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,888 shares in the last quarter. Finally, Blair William & Co. IL purchased a new position in Radius Health in the 2nd quarter valued at $205,000.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.